Abbisko Therapeutics Obtained Approval from U.S. FDA for Pivotal Global Multi-center Phase III Clinical Trial of CSF-1R Inhibitor Pimicotinib (ABSK021)

Mar 16,2023

Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376

Mar 01,2023

Abbisko therapeutic announces the IND approval by NMPA for its next-generation FGFR inhibitor ABSK121

Feb 22,2023

EXPANDED ACCESS POLICY

Feb 01,2023

Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）

Jan 30,2023

Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021）in cGVHD

Jan 17,2023

Abbisko Therapeutics announces preliminary Phase I safety and efficacy results of Irpagratinib (ABSK011) in patients in second-line hepatocellular carcinoma with FGF19 overexpression

Dec 15,2022

Abbisko Therapeutics announces preliminary Phase II safety and efficacy results of Fexagratinib (ABSK091) in patients with urothelial carcinoma

Dec 08,2022

Preliminary Phase Ib results of ABSK021 for advanced TGCT will be published at the 2022 CTOS annual meeting

Nov 15,2022

Abbisko Therapeutics completed the first patient enrollment in the Phase II clinical trial for ABSK091 in combination with BeiGene’s Tislelizumab in urothelial carcinoma

Nov 04,2022

Abbisko Therapeutic announces the clinical trial approval granted by U.S. FDA for its next-generation FGFR inhibitor ABSK121

Nov 01,2022

Abbisko Therapeutics obtained pivotal Phase III clinical trial approval for CSF-1R inhibitor ABSK021 from the CDE of NMPA

Oct 25,2022

Abbisko Therapeutics Completed Dosing of First Patient in China for Its Small-Molecule PD-L1 Inhibitor ABSK043

Sep 27,2022

Abbisko Therapeutics won the 2022 "Future Star" Award of the biopharmaceutical industry

Aug 15,2022

Abbisko Therapeutics announces China NMPA breakthrough therapy designation granted for its CSF-1R inhibitor ABSK021

Jul 20,2022

Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061

Jul 04,2022

Abbisko Therapeutics Announces the Appointment of Dr. Zidong Zhang as CFO

May 16,2022

Abbisko Therapeutics Declared Two Next-Generation Precision Oncology Preclinical Candidates and Will Present Multiple Discovery and Translational Research Results at AACR Annual Meeting 2022

Mar 11,2022

Abbisko Therapeutics Has Obtained IND Approval for ABSK061, an Innovative and Highly Selective FGFR2/3 Inhibitor, from the NMPA

Mar 03,2022

Abbisko Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate ABSK091 in Combination with Tislelizumab

Feb 15,2022

Abbisko Therapeutics Completes Dosing of the First Patient in the Phase II Clinical Trial for ABSK011 in Combination with an Anti-PD-L1 Antibody

Feb 08,2022

Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules

Jan 18,2022

Abbisko Therapeutics Completes Dosing of the First Patient in the Phase II Clinical Study for FGFR Inhibitor ABSK091 (AZD4547) in Urothelial Cancer

Dec 02,2021

Abbisko Therapeutics Completes Dosing of the First Subject in the Dose Expansion Part of Phase I Trial for CSF-1R Inhibitor ABSK021

Nov 17,2021

Abbisko’s Partner X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome

Nov 03,2021

Abbisko Therapeutics R&D and Manufacturing Facility Landed in Zhangjiang

Oct 29,2021

Abbisko Therapeutics Obtained Clinical Trial Approval for ABSK061, A Selective Inhibitor of FGFR2 and FGFR3, by the U.S. FDA

Oct 25,2021

Abbisko Therapeutics Announces the IND Approval by NMPA for Phase II Clinical Trial of ABSK011

Oct 19,2021

Abbisko Cayman Limited successfully landed on the Hong Kong Stock Exchange

Oct 15,2021

Abbisko Therapeutics Announces Dosing of First Patient in A Phase I Clinical Study of ABSK043 In Australia

Sep 03,2021

Abbisko Therapeutics Obtained Clinical Trial Approval for ABSK043 in Australia

Jul 12,2021

Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China

Jul 05,2021

Abbisko Therapeutics Announces Dosing of First Patient in A Phase Ib Clinical Study of ABSK011 In China

Jun 29,2021

Abbisko Therapeutics Announces the Appointment of Mr. Yongyi Li as General Counsel

Jun 04,2021

Abbisko Therapeutics Announces the Appointment of Ms. Jia Feng as Executive Director and Head of Human Resource

Jun 04,2021

Abbisko Therapeutics and AstraZeneca China Announce Strategic Partnership

May 25,2021

Burning Rock and Abbisko Therapeutics Announce Strategic Partnership on Co-development of Companion Diagnostics for ABSK091

Apr 29,2021

Abbisko Therapeutics Announces the Appointment of Dr. Zhen Zhang as CMC VP

Apr 19,2021

Abbisko Therapeutics Announces the Appointment of Dr. Jing Ji as Chief Medical Officer

Feb 18,2021

Abbisko Therapeutics Featured at the 39th Annual J.P. Morgan Healthcare Conference

Jan 19,2021

Abbisko Therapeutics Announces the Appointment of Dr. Xie Kewei as Chief Business Officer

Jan 12,2021

Abbisko Therapeutics Announces the Completion of $123 Million Series D Financing Led by The Carlyle Group

Jan 08,2021

Abbisko Therapeutics Announces the Appointment of Mr. Ye Lin as Chief Financial Officer

Nov 16,2020

Abbisko Therapeutics Obtained ABSK021 IND Approval in China

Oct 29,2020

Abbisko Therapeutics Obtained IND approval for Phase 1b/II Clinical Trial of Mavorixafor in Combination with Toripalimab in China

Sep 09,2020

Abbisko Therapeutics Announces $70M Series C Financing Led by Temasek

Mar 25,2020

Abbisko Therapeutics Announces Receiving of the IND Approval by the China NMPA for ABSK-011, A Novel FGFR4 Inhibitor

Mar 09,2020

Abbisko Therapeutics Announces the IND Approval of a Novel FGFR4 Inhibitor ABSK011 by the Taiwan FDA

Dec 06,2019

Abbisko Therapeutics Announces Initiation of Phase 1 Trial for ABSK021, its Selective CSF-1R Small Molecule Inhibitor

Aug 19,2019

X4 Pharmaceuticals and Abbisko Therapeutics Enter into Oncology Development and Commercialization Agreement for Mavorixafor in Greater China

Jul 17,2019

Abbisko Therapeutics Wins the Zhangjiang Science City Innovation & Progress Award for Outstanding Enterprises

Jan 18,2019

Abbisko Therapeutics is Awarded as One of the Most Promising Enterprises Founded by Foreign-educated Returnees

Dec 23,2018

Shanghai Mayor Ying Yong Presents Abbisko Therapeutics with “MNC’s R&D Centers” Certificate

Dec 07,2018

Dr. Hongping Yu Attends and Delivers a Speech at ACS Conference

Oct 28,2018

Abbisko Wins the Best Biomedical Investment Case Award in the Healthcare Investment Rankings 2018

Mar 30,2018

Dr. Yao-chang Xu Attends the Hong Kong Biotech Summit 2018

Mar 23,2018

Dr. Yao-chang Xu Presents at the BIO Asia International Conference

Mar 21,2018

Dr. Zhui Chen Attends China Healthcare Investment & Partnering Symposium 2018 on Invitation

Mar 16,2018

Dr. Yao-chang Xu Attends Zhangjiang League of Makers Health Industry Association’s Inauguration

Nov 20,2017

Dr. Yao-chang Xu Gives a Lecture at Peking University Clinical Research Institute

Apr 06,2017

Abbisko Completes Series A Round Financing of $ 28 Million

Feb 05,2017

Dr. Hongping Yu Attends a Teach-in at Nankai University on Invitation

Nov 24,2016

Dr. Yao-chang Xu Attends Bank of America Merrill Lynch China Annual Conference 2016 and Delivers a Speech

Nov 01,2016